| 名稱 | LMNA-NTRK1/BaF3 |
| 型號 | CBP73202 |
| 報(bào)價(jià) |  |
| 特點(diǎn) | LMNA-NTRK1/BaF3,母細(xì)胞：BaF3，凍存條件：90% FBS+10% DMSO |
產(chǎn)品搜索
相關(guān)文章
- 如何正確的進(jìn)行ELISA試劑盒的操作
- 【新品發(fā)布】血液系統(tǒng)惡性腫瘤標(biāo)準(zhǔn)品-27基因-38位點(diǎn)
- IL-21藥篩細(xì)胞模型
- 研究揭示缺氧如何導(dǎo)致細(xì)菌引發(fā)痤瘡
- 選擇性組蛋白去乙酰化酶抑制劑在腫瘤免疫治療中的作用及前景
- ADCC/ADCP細(xì)胞篩選模型
- 【產(chǎn)品推介】TIGIT靶點(diǎn)細(xì)胞篩選模型
- 【產(chǎn)品推介】LAG3&PD-1/L1雙靶點(diǎn)細(xì)胞篩選模型
- 【新品上線】TIM-3細(xì)胞篩選模型
- 從人結(jié)腸癌細(xì)胞株延伸出早期結(jié)腸癌治療方法
聯(lián)系我們
聯(lián)系人：蔣經(jīng)理
電話：4008750250
號碼：
手機(jī)：18066071954
地址：南京市棲霞區(qū)緯地路9號
Email： [email protected]
電話：4008750250
號碼：
手機(jī)：18066071954
地址：南京市棲霞區(qū)緯地路9號
Email： [email protected]
產(chǎn)品展示 / PRODUCTS
藥靶細(xì)胞株 > kinase激酶細(xì)胞株 > CBP73202LMNA-NTRK1/BaF3
- 詳細(xì)內(nèi)容
CBP73202 | |
| I. Introduction | |
Cell Line Name： | LMNA-NTRK1/BaF3 |
Host Cell: | BA/F3 |
| Stability: | 16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
Application: | Anti-proliferation assay and PD assay |
Freeze Medium: | 90% FBS+10% DMSO |
Complete Culture Medium: | RPMI-1640+10%FBS+2ug/ml puromycin |
Mycoplasma Status: | Negative |
| II.Background | |
NTRK1 rearrangements involve the kinase domain of the NTRK1 gene which includes 17 exons located on chromosome 1q21-22 (Alberti et al. 2003). The frequency of NTRK1 fusions in patients with adenocarcinoma histology is 3.3% of cases (3 out of 91 patients; Vaishnavi et al. 2013). a In preclinical studies, cell lines expressing MPRIP-NTRK1 or CD74-NTRK1 were inhibited by ARRY-470, a TRKA/B/C inhibitor (Vaishnavi et al. 2013). b In preclinical studies, cell lines expressing MPRIP-NTRK1 or CD74-NTRK1 were inhibited by lestaurtinib, a FLT3/TRKA inhibitor (Vaishnavi et al. 2013). c A patient with non-small cell lung cancer harboring an MPRIP-NTRK1 fusion mutation was treated with crizotinib, which has activity against TRKA in addition to ALK, MET and ROS1 (Vaishnavi et al. 2013). The patient demonstrated a small radiographic decrease in tumor size but experienced disease progression after three months (Vaishnavi et al. 2013) | |
| III. Representative Data | |
1. WB of LMNA-NTRK1/BaF3 expression | |
| |
2. Sanger of LMNA-NTRK1/BaF3 expression
Figure 2. Sanger Sequencing of LMNA-NTRK1/BaF3 | |
3. Anti-proliferation assay | |
| |
Figure 3. Anti-proliferation assay of two reference compounds on the LMNA-NTRK1/BaF3 Stable Cell Line | |
員_a.png)